Bio­Marin lays out its PhI­II strat­e­gy for its close­ly-watched gene ther­a­py for he­mo­phil­ia A

When it comes to gene ther­a­py stud­ies, any­thing oth­er than a per­fect score al­ways rais­es a red flag about their fu­ture in late-stage test­ing. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland